Analysis of factors associated with the development of tobramycin (TO) resistance in Cystic Fibrosis (CF) patients

W. Stratbucker, John Louis Colombo, T. Hallberg, Paul Henry Sammut

Research output: Contribution to journalArticle

Abstract

PURPOSE: Emergence of aminoglycoside-resistant stains of gram-negative bacteria in CF patients is a disturbing finding which may be associated with rapid pulmonary deterioration. The purpose of this study was to help determine what factors precede infection with TO-resistant (TR) gram negative bacteria. METHODS: Eleven CF patients with TR bacterial infection were identified, 8 with Pseudomonas aeruginosa, two with Pseudomonas cepacia, and one with Xanthamonas maltophilia. A case-control group was chosen with matching by age, lung severity (FVC and FEV1 values) and, in all but one case, by sex. All patients were identified by retrospective chart review. The date of first positive culture for TR organism, and corresponding date for the case-controls, served as the end point for a 12-month time period in which treatment data were analyzed for both groups. Variables analyzed included days hospitalized, days of intravenous (IV) antibiotics, days of IV TO, days of oral Ciprofloxacin (CP), days of oral antibiotics excluding CP, days of aerosolized antibiotics, and days of aerosolized TO. Student's t-test was used to compare the data. If values were non-parametric, a Mann-Whitney Rank Sum test was used. RESULTS: There was a significant difference between the case and control groups only in the number of days of aerosolized TO (P=.031, Mann-Whitney). The difference in days of IV TO approached significance (P=.054, Mann-Whitney). CONCLUSIONS: In this small group of patients, the data suggests that the use of aerosolized TO is closely associated with the development of TR gram-negative bacterial infection in CF. CLINICAL IMPLICATIONS: The risk of developing TR with use of aerosolized TO in CF patients should be considered when using this mode of therapy.

Original languageEnglish (US)
JournalChest
Volume110
Issue number4 SUPPL.
StatePublished - Oct 1 1996

Fingerprint

Tobramycin
Cystic Fibrosis
Statistical Factor Analysis
Ciprofloxacin
Anti-Bacterial Agents
Gram-Negative Bacteria
Gram-Negative Bacterial Infections
Burkholderia cepacia
Lung
Control Groups
Aminoglycosides
Nonparametric Statistics
Bacterial Infections
Pseudomonas aeruginosa
Coloring Agents
Students
Therapeutics
Infection

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Analysis of factors associated with the development of tobramycin (TO) resistance in Cystic Fibrosis (CF) patients. / Stratbucker, W.; Colombo, John Louis; Hallberg, T.; Sammut, Paul Henry.

In: Chest, Vol. 110, No. 4 SUPPL., 01.10.1996.

Research output: Contribution to journalArticle

@article{884f450e382c46b5ad345697dba8ee8a,
title = "Analysis of factors associated with the development of tobramycin (TO) resistance in Cystic Fibrosis (CF) patients",
abstract = "PURPOSE: Emergence of aminoglycoside-resistant stains of gram-negative bacteria in CF patients is a disturbing finding which may be associated with rapid pulmonary deterioration. The purpose of this study was to help determine what factors precede infection with TO-resistant (TR) gram negative bacteria. METHODS: Eleven CF patients with TR bacterial infection were identified, 8 with Pseudomonas aeruginosa, two with Pseudomonas cepacia, and one with Xanthamonas maltophilia. A case-control group was chosen with matching by age, lung severity (FVC and FEV1 values) and, in all but one case, by sex. All patients were identified by retrospective chart review. The date of first positive culture for TR organism, and corresponding date for the case-controls, served as the end point for a 12-month time period in which treatment data were analyzed for both groups. Variables analyzed included days hospitalized, days of intravenous (IV) antibiotics, days of IV TO, days of oral Ciprofloxacin (CP), days of oral antibiotics excluding CP, days of aerosolized antibiotics, and days of aerosolized TO. Student's t-test was used to compare the data. If values were non-parametric, a Mann-Whitney Rank Sum test was used. RESULTS: There was a significant difference between the case and control groups only in the number of days of aerosolized TO (P=.031, Mann-Whitney). The difference in days of IV TO approached significance (P=.054, Mann-Whitney). CONCLUSIONS: In this small group of patients, the data suggests that the use of aerosolized TO is closely associated with the development of TR gram-negative bacterial infection in CF. CLINICAL IMPLICATIONS: The risk of developing TR with use of aerosolized TO in CF patients should be considered when using this mode of therapy.",
author = "W. Stratbucker and Colombo, {John Louis} and T. Hallberg and Sammut, {Paul Henry}",
year = "1996",
month = "10",
day = "1",
language = "English (US)",
volume = "110",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Analysis of factors associated with the development of tobramycin (TO) resistance in Cystic Fibrosis (CF) patients

AU - Stratbucker, W.

AU - Colombo, John Louis

AU - Hallberg, T.

AU - Sammut, Paul Henry

PY - 1996/10/1

Y1 - 1996/10/1

N2 - PURPOSE: Emergence of aminoglycoside-resistant stains of gram-negative bacteria in CF patients is a disturbing finding which may be associated with rapid pulmonary deterioration. The purpose of this study was to help determine what factors precede infection with TO-resistant (TR) gram negative bacteria. METHODS: Eleven CF patients with TR bacterial infection were identified, 8 with Pseudomonas aeruginosa, two with Pseudomonas cepacia, and one with Xanthamonas maltophilia. A case-control group was chosen with matching by age, lung severity (FVC and FEV1 values) and, in all but one case, by sex. All patients were identified by retrospective chart review. The date of first positive culture for TR organism, and corresponding date for the case-controls, served as the end point for a 12-month time period in which treatment data were analyzed for both groups. Variables analyzed included days hospitalized, days of intravenous (IV) antibiotics, days of IV TO, days of oral Ciprofloxacin (CP), days of oral antibiotics excluding CP, days of aerosolized antibiotics, and days of aerosolized TO. Student's t-test was used to compare the data. If values were non-parametric, a Mann-Whitney Rank Sum test was used. RESULTS: There was a significant difference between the case and control groups only in the number of days of aerosolized TO (P=.031, Mann-Whitney). The difference in days of IV TO approached significance (P=.054, Mann-Whitney). CONCLUSIONS: In this small group of patients, the data suggests that the use of aerosolized TO is closely associated with the development of TR gram-negative bacterial infection in CF. CLINICAL IMPLICATIONS: The risk of developing TR with use of aerosolized TO in CF patients should be considered when using this mode of therapy.

AB - PURPOSE: Emergence of aminoglycoside-resistant stains of gram-negative bacteria in CF patients is a disturbing finding which may be associated with rapid pulmonary deterioration. The purpose of this study was to help determine what factors precede infection with TO-resistant (TR) gram negative bacteria. METHODS: Eleven CF patients with TR bacterial infection were identified, 8 with Pseudomonas aeruginosa, two with Pseudomonas cepacia, and one with Xanthamonas maltophilia. A case-control group was chosen with matching by age, lung severity (FVC and FEV1 values) and, in all but one case, by sex. All patients were identified by retrospective chart review. The date of first positive culture for TR organism, and corresponding date for the case-controls, served as the end point for a 12-month time period in which treatment data were analyzed for both groups. Variables analyzed included days hospitalized, days of intravenous (IV) antibiotics, days of IV TO, days of oral Ciprofloxacin (CP), days of oral antibiotics excluding CP, days of aerosolized antibiotics, and days of aerosolized TO. Student's t-test was used to compare the data. If values were non-parametric, a Mann-Whitney Rank Sum test was used. RESULTS: There was a significant difference between the case and control groups only in the number of days of aerosolized TO (P=.031, Mann-Whitney). The difference in days of IV TO approached significance (P=.054, Mann-Whitney). CONCLUSIONS: In this small group of patients, the data suggests that the use of aerosolized TO is closely associated with the development of TR gram-negative bacterial infection in CF. CLINICAL IMPLICATIONS: The risk of developing TR with use of aerosolized TO in CF patients should be considered when using this mode of therapy.

UR - http://www.scopus.com/inward/record.url?scp=33750271688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750271688&partnerID=8YFLogxK

M3 - Article

VL - 110

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4 SUPPL.

ER -